USPTO allows patent to biomedical company Nurexone
Canadian Manufacturing
JANUARY 16, 2023
The patent covers and protects NurExone Exo-PTEN technology, and its drug composition as well as methods for non-invasive intranasal administration of exosome-based treatment. The Patent will enable us to strengthen the IP barrier protecting our core technology, including the source of the cells, loaded siRNA and method of administration.
Let's personalize your content